JP2015086181A - Citrus junos seed extract-containing composition, food product and pharmaceutical - Google Patents
Citrus junos seed extract-containing composition, food product and pharmaceutical Download PDFInfo
- Publication number
- JP2015086181A JP2015086181A JP2013226583A JP2013226583A JP2015086181A JP 2015086181 A JP2015086181 A JP 2015086181A JP 2013226583 A JP2013226583 A JP 2013226583A JP 2013226583 A JP2013226583 A JP 2013226583A JP 2015086181 A JP2015086181 A JP 2015086181A
- Authority
- JP
- Japan
- Prior art keywords
- seed extract
- limonoid
- yuzu
- yuzu seed
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 235000013305 food Nutrition 0.000 title claims abstract description 20
- 229940059458 citrus junos seed extract Drugs 0.000 title abstract 5
- 241000951471 Citrus junos Species 0.000 claims abstract description 70
- 150000002630 limonoids Chemical class 0.000 claims abstract description 41
- 210000002027 skeletal muscle Anatomy 0.000 claims abstract description 28
- 210000000577 adipose tissue Anatomy 0.000 claims abstract description 22
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 claims abstract description 4
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 claims description 35
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 claims description 35
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 claims description 35
- VHLJDTBGULNCGF-UHFFFAOYSA-N Limonin Natural products CC1(C)OC2CC(=O)OCC23C4CCC5(C)C(CC(=O)C6OC56C4(C)C(=O)CC13)c7cocc7 VHLJDTBGULNCGF-UHFFFAOYSA-N 0.000 claims description 8
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 11
- 230000009467 reduction Effects 0.000 abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 239000003925 fat Substances 0.000 description 19
- 238000009395 breeding Methods 0.000 description 12
- 230000001488 breeding effect Effects 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000002798 polar solvent Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 235000020971 citrus fruits Nutrition 0.000 description 6
- 201000010063 epididymitis Diseases 0.000 description 6
- FYIKIBQJAJRKQM-UHFFFAOYSA-N limonoid glycoside Natural products CC1(C)OC2CC(=O)OCC22C1CC(=O)C(C13C(O3)C(O)=O)(C)C2CCC1(C)C(C1=COC=C1)OC1OC(CO)C(O)C(O)C1O FYIKIBQJAJRKQM-UHFFFAOYSA-N 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 210000004003 subcutaneous fat Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 241000207199 Citrus Species 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- -1 Limonoid glycosides Chemical class 0.000 description 1
- ZIKZPLSIAVHITA-UHFFFAOYSA-N Nomilinic acid Natural products CC(=O)OC(CC(O)=O)C1(C)C(C(C)(C)O)CC(=O)C(C23OC2C(=O)O2)(C)C1CCC3(C)C2C=1C=COC=1 ZIKZPLSIAVHITA-UHFFFAOYSA-N 0.000 description 1
- MAYJEFRPIKEYBL-OASIGRBWSA-N Obacunone Chemical group C=1([C@@H]2OC(=O)[C@H]3O[C@@]43[C@]3(C)C(=O)C[C@H]5C(C)(C)OC(=O)C=C[C@]5(C)[C@H]3CC[C@]42C)C=COC=1 MAYJEFRPIKEYBL-OASIGRBWSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 125000003472 limonin group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- KPDOJFFZKAUIOE-WNGDLQANSA-N nomilin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@H]2C(C)(C)OC(=O)C[C@@H]([C@]42C)OC(=O)C)C=COC=1 KPDOJFFZKAUIOE-WNGDLQANSA-N 0.000 description 1
- KPDOJFFZKAUIOE-HPFWCIFASA-N nomilin Natural products O=C(O[C@H]1[C@@]2(C)[C@@H](C(C)(C)OC(=O)C1)CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@H](c3cocc3)OC(=O)[C@@H]3O[C@@]123)C KPDOJFFZKAUIOE-HPFWCIFASA-N 0.000 description 1
- VSLDMVSILHVDSR-UHFFFAOYSA-N obacunone Natural products CC1(C)OC(=O)C=CC2(C)C1CC(=O)C3(C)C2CCC4(C)C(OC(=O)C5OC345)c6occc6 VSLDMVSILHVDSR-UHFFFAOYSA-N 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、ユズ種子抽出物含有組成物、食品および医薬品に係り、特に、新規な用途を有するユズ種子抽出物含有組成物、食品および医薬品に関する。 The present invention relates to a yuzu seed extract-containing composition, food, and pharmaceutical, and more particularly, to a yuzu seed extract-containing composition, food, and pharmaceutical having a novel use.
柑橘類（ムクロジ目ミカン科ミカン属）の果実は、生食、ジュース、製菓材料、料理の風味付け等として世界各地で広く利用されている。また、柑橘類にはビタミンＣや食物繊維等が豊富に含まれていることから、柑橘類の果実は、健康の増進に寄与する食物であると認識されている。
この柑橘類のなかでも、特に、ユズ（学名：Ｃｉｔｒｕｓ ｊｕｎｏｓ）については、最近の研究において、様々な優れた機能を有するとの報告がなされている。
The fruits of citrus fruits (Muclidae) are widely used around the world as raw foods, juices, confectionery materials, and flavoring dishes. Moreover, since citrus fruits are rich in vitamin C, dietary fiber, and the like, citrus fruits are recognized as foods that contribute to health promotion.
Among these citrus fruits, especially Yuzu (scientific name: Citrus junos) has been reported in recent studies to have various excellent functions.
例えば、特許文献１には、ユズ抽出物が、ヒアルロン酸産生能を促進させる機能を有することが開示されている。さらに、特許文献２には、ユズの単細胞化処理物が、角質を剥離させる機能を有することが開示されている。
つまり、特許文献１および特許文献２には、ユズ抽出物の用途（ヒアルロン酸産生能促進用、角質剥離用）が開示されている。
For example, Patent Document 1 discloses that a yuzu extract has a function of promoting hyaluronic acid production ability. Further, Patent Document 2 discloses that a single cellized product of Yuzu has a function of exfoliating keratin.
That is, Patent Literature 1 and Patent Literature 2 disclose uses of a yuzu extract (for promoting hyaluronic acid production ability, for exfoliating keratin).
しかしながら、ユズ抽出物には、特許文献１および特許文献２に開示されているような機能だけではなく、これらの機能の他に、今までに見出されていない機能が存在する可能性がある。 However, in the yuzu extract, there is a possibility that not only functions disclosed in Patent Document 1 and Patent Document 2 but also functions that have not been found so far exist in addition to these functions. .
そこで、本発明は、ユズ抽出物（詳細には、ユズ種子抽出物）の全く新たな機能を見出し、新たな用途のユズ種子抽出物含有組成物、食品および医薬品を提供することを課題とする。 Then, this invention makes it a subject to discover the completely new function of a yuzu extract (specifically yuzu seed extract), and to provide the yuzu seed extract containing composition, foodstuff, and pharmaceutical for a new use. .
前記課題は、以下の手段により解決することができる。
（１）ユズ種子抽出物由来のリモノイドアグリコンを含有し、骨格筋増量用であることを特徴とするユズ種子抽出物含有組成物。
（２）体脂肪低減用であることを特徴とする前記（１）に記載のユズ種子抽出物組成物。
（３）前記リモノイドアグリコンは、リモニン、ノミリン、デアセチルノミリン、およびオバクノンを含んで構成されることを特徴とする前記（１）または前記（２）に記載のユズ種子抽出物含有組成物。
（４）前記リモノイドアグリコンを２．５〜４質量％含有することを特徴とする前記（１）ないし前記（３）のいずれか１つに記載のユズ種子抽出物含有組成物。
（５）前記（１）ないし前記（４）のいずれか１つに記載のユズ種子抽出物含有組成物を含有することを特徴とする食品。
（６）前記（１）ないし前記（４）のいずれか１つに記載のユズ種子抽出物含有組成物を有効成分として含有することを特徴とする医薬品。
The above problem can be solved by the following means.
(1) A composition containing a yuzu seed extract, which contains a limonoid aglycone derived from a yuzu seed extract and is used for increasing skeletal muscle.
(2) The yuzu seed extract composition as described in (1) above, which is used for reducing body fat.
(3) The yuzu seed extract-containing composition as described in (1) or (2) above, wherein the limonoid aglycone comprises limonin, nomiline, deacetylnomyrin, and obacnon.
(4) The yuzu seed extract-containing composition according to any one of (1) to (3), wherein the limonoid aglycone is contained in an amount of 2.5 to 4% by mass.
(5) A food comprising the yuzu seed extract-containing composition according to any one of (1) to (4).
(6) A pharmaceutical comprising the yuzu seed extract-containing composition according to any one of (1) to (4) as an active ingredient.
本発明に係るユズ種子抽出物含有組成物は、ユズ種子抽出物由来のリモノイドアグリコンを含有することにより、腓腹筋等の骨格筋を増量させることができ、骨格筋増量用の組成物として好適に用いることができる。
また、本発明に係るユズ種子抽出物含有組成物は、ユズ種子抽出物由来のリモノイドアグリコンを含有することにより、体脂肪を低減させることができ、体脂肪低減用の組成物として好適に用いることができる。
The composition containing a yuzu seed extract according to the present invention can increase the amount of skeletal muscles such as gastrocnemius muscle by containing limonoid aglycone derived from the yuzu seed extract, and is suitably used as a composition for increasing skeletal muscle. be able to.
Moreover, the yuzu seed extract containing composition which concerns on this invention can reduce body fat by containing the limonoid aglycone derived from a yuzu seed extract, and uses it suitably as a composition for body fat reduction. Can do.
本発明に係る食品および医薬品は、前記のユズ種子抽出物含有組成物を含有することから、骨格筋を増量させるという効果を発揮することができる。
また、本発明に係る食品および医薬品は、前記のユズ種子抽出物含有組成物を含有することから、体脂肪を低減させるという効果を発揮することができる。
Since the foodstuff and the pharmaceutical which concern on this invention contain the said yuzu seed extract containing composition, the effect of increasing a skeletal muscle can be exhibited.
Moreover, since the foodstuff and pharmaceutical which concern on this invention contain the said yuzu seed extract containing composition, it can exhibit the effect of reducing body fat.
以下、本発明に係るユズ種子抽出物含有組成物、食品および医薬品を実施するための形態（実施形態）について説明する。 Hereinafter, the form (embodiment) for implementing the yuzu seed extract containing composition, foodstuff, and pharmaceutical which concern on this invention is demonstrated.
≪ユズ種子抽出物含有組成物≫
本実施形態に係るユズ種子抽出物含有組成物（以下、適宜「組成物」という）は、骨格筋増量用であることを特徴とする。さらに、本実施形態に係る組成物は、体脂肪低減用であることが好ましい。
また、本実施形態に係る組成物は、ユズ種子抽出物由来のリモノイドアグリコンを含有することを特徴とし、リモノイドアグリコンは、リモニン、ノミリン、デアセチルノミリン、およびオバクノンを含んで構成されることが好ましい。
以下、本実施形態に係るユズ種子抽出物含有組成物について、まず、ユズ種子抽出物および用途について説明し、その後、組成物の構成を説明する。
≪Composition containing yuzu seed extract≫
The yuzu seed extract-containing composition according to the present embodiment (hereinafter referred to as “composition” as appropriate) is used for increasing skeletal muscle mass. Furthermore, the composition according to this embodiment is preferably used for reducing body fat.
Further, the composition according to the present embodiment is characterized in that it contains a limonoid aglycone derived from a yuzu seed extract, and the limonoid aglycone comprises limonin, nomiline, deacetylnomyrin, and obacnone. preferable.
Hereinafter, with respect to the yuzu seed extract-containing composition according to the present embodiment, first, the yuzu seed extract and use will be described, and then the configuration of the composition will be described.
［ユズ種子抽出物］
ユズ種子抽出物とは、ムクロジ目ミカン科ミカン属（柑橘類）のユズ（学名：Ｃｉｔｒｕｓ ｊｕｎｏｓ）の種子から抽出して得られる抽出物である。
なお、発明者らは、ムクロジ目ミカン科ミカン属に属する複数の果実の様々な部位の組成等を確認したところ、ユズの中でも特に種子部分の抽出物に、骨格筋増量や体脂肪低減という機能を向上させるリモノイドアグリコンが多く含まれていることを確認した。
よって、ユズ種子抽出物のリモノイドアグリコンを用いることにより、少量の原料（ユズ種子）から多量のリモノイドアグリコンを得ることができるため、原料の使用量や原料コストを抑えることができるとともに、製造工程における抽出作業の負担の軽減や抽出時間の短縮にもつながる。
[Yuzu seed extract]
A yuzu seed extract is an extract obtained by extracting from the seed of the citron (Citrus junos) of the citrus citrus genus (citrus).
In addition, when the inventors confirmed the composition of various parts of a plurality of fruits belonging to the genus Citrus mandarinaceae, the extract of the seed part, among others, functions of increasing skeletal muscle and reducing body fat. It was confirmed that a large amount of limonoid aglycone was improved.
Therefore, since a large amount of limonoid aglycone can be obtained from a small amount of raw material (YUZU SEED) by using limonoid aglycone of YUZU SEED EXTRACT, the amount of raw material used and raw material cost can be suppressed, and in the manufacturing process It also reduces the burden of extraction work and shortens the extraction time.
［用途］
本実施形態に係るユズ種子抽出物含有組成物の新規な用途としては、次に示す用途が存在する。
[Usage]
The following uses exist as a novel use of the yuzu seed extract containing composition which concerns on this embodiment.
（骨格筋増量用）
骨格筋増量用とは、骨格筋の量を増やすという用途であり、詳細な用途としては、骨格筋増量用食品（健康食品）や骨格筋増量用医薬品である。
ここで、骨格筋とは、筋肉の一分類であり、骨格を動かす筋肉を示す。そして、骨格筋としては、例えば、腓腹筋等がある。
(For skeletal muscle gain)
The skeletal muscle weight increase is used to increase the amount of skeletal muscle, and the detailed use is a food for skeletal muscle weight gain (health food) and a drug for skeletal muscle weight gain.
Here, the skeletal muscle is a class of muscle and indicates a muscle that moves the skeleton. Examples of skeletal muscle include gastrocnemius muscle.
（体脂肪低減用）
体脂肪低減用とは、体脂肪の量を減らすという用途であり、詳細な用途としては、体脂肪低減用食品（健康食品）や体脂肪低減用医薬品である。
そして、体脂肪（脂肪組織）としては、例えば、腎臓周囲脂肪、腸間膜脂肪、精巣上体周囲脂肪、皮下脂肪等がある。
(For body fat reduction)
“For body fat reduction” refers to an application for reducing the amount of body fat, and specific applications include food for reducing body fat (health food) and pharmaceuticals for reducing body fat.
Examples of the body fat (adipose tissue) include perirenal fat, mesenteric fat, epididymal fat, and subcutaneous fat.
［組成物の構成］
本実施形態に係る組成物は、リモノイドアグリコン、リモノイドグリコシドを含んで構成される。
［リモノイドアグリコン］
リモノイドアグリコンは、ユズ種子抽出物由来のもの（ユズ種子抽出物に含まれているもの）であり、骨格筋を増量させたり、体脂肪を低減させたりするという効果を発揮する化合物群である。
[Composition of composition]
The composition according to this embodiment includes a limonoid aglycone and a limonoid glycoside.
[Limonoid aglycon]
Limonoid aglycones are derived from Yuzu seed extract (included in Yuzu seed extract), and are a group of compounds that exert the effect of increasing skeletal muscles or reducing body fat.
そして、リモノイドアグリコンのリモノイドとは、ユズ等の柑橘類の植物に多く含まれる天然の化学物質（フィトケミカル）のことであり、化学構造的にはフラノラクトン骨格を有する化学物質である。また、リモノイドアグリコンのアグリコンとは、グリコシド（配糖体）から糖部分が外れた非糖状態を示すものである。 The limonoid of the limonoid aglycone is a natural chemical substance (phytochemical) that is abundant in citrus plants such as yuzu, and is a chemical substance having a furanolactone skeleton in terms of chemical structure. The aglycone of limonoid aglycone indicates a non-sugar state in which the sugar moiety is removed from the glycoside (glycoside).
そして、リモノイドアグリコンは、以下に示すリモニン、ノミリン、デアセチルノミリン、およびオバクノンを含んで構成される。 And a limonoid aglycone is comprised including the following limonin, nomiline, deacetyl nomiline, and an ovacone.
（リモニン）
リモニン（Ｃ２６Ｈ３０Ｏ８）とは、以下の構造式により表される。
Limonin (C 26 H 30 O 8 ) is represented by the following structural formula.
（ノミリン）
ノミリン（Ｃ２８Ｈ３４Ｏ９）とは、以下の構造式により表される。
Nomiline (C 28 H 34 O 9 ) is represented by the following structural formula.
（デアセチルノミリン）
デアセチルノミリン（Ｃ２６Ｈ３２Ｏ８）とは、以下の構造式により表される。
Deacetylnomyrin (C 26 H 32 O 8 ) is represented by the following structural formula.
（オバクノン）
オバクノン（Ｃ２６Ｈ３０Ｏ７）とは、以下の構造式により表される。
Obacnon (C 26 H 30 O 7 ) is represented by the following structural formula.
［リモノイドグリコシド］
リモノイドグリコシドは、ユズ種子抽出物由来のもの（ユズ種子抽出物に含まれているもの）であり、前記したリモノイドアグリコンに糖が結合（グリコシド結合）した化合物群である。
[Limonoid glycoside]
Limonoid glycosides are derived from YUZU SEED EXTRACT (included in YUZU SEED EXTRACT), and are a group of compounds in which a sugar is bonded (glycoside bond) to the limonoid aglycone described above.
［その他の含有物］
本実施形態に係る組成物は、前記したリモノイドアグリコンおよびリモノイドグリコシド以外にも、抽出残渣である糖類などを含んでいてもよい。
また、本実施形態に係る組成物は、食品や医薬品等の素材（材料）として好適に用いる形態とするため、例えば、粉末状、顆粒状、粒状、ペースト状、ゲル状、固形状、カプセル型、または、液体状とすることができる。
[Other inclusions]
The composition according to the present embodiment may contain a saccharide as an extraction residue in addition to the above-described limonoid aglycone and limonoid glycoside.
In addition, the composition according to the present embodiment is preferably used as a raw material (material) such as food or medicine, and thus, for example, powder, granule, granule, paste, gel, solid, capsule type Or in liquid form.
次に、前記した本実施形態に係るユズ種子抽出物含有組成物を含有する食品について説明する。
≪食品≫
本実施形態に係る食品とは、前記した組成物を含有する食品であり、骨格筋増量用や体脂肪低減用の健康食品として利用することができる。
そして、本実施形態に係る食品とは、例えば、菓子、パン、牛乳、各種飲料、うどん、そば、パスタ、米飯、調味料、香辛料、惣菜、油脂含有食品、酒類、清涼飲料が挙げられる。なお、本実施形態に係る食品は、前記した食品の種類に応じて、当業者に公知の各種成分を配合して構成すればよい。
Next, the foodstuff containing the yuzu seed extract containing composition which concerns on above-described this embodiment is demonstrated.
≪Food≫
The food according to the present embodiment is a food containing the above-described composition, and can be used as a health food for increasing skeletal muscle or reducing body fat.
The food according to the present embodiment includes, for example, confectionery, bread, milk, various beverages, udon, soba, pasta, cooked rice, seasonings, spices, sugar beet, oil and fat-containing foods, alcoholic beverages, and soft drinks. In addition, what is necessary is just to comprise the foodstuff which concerns on this embodiment by mix | blending various components well-known to those skilled in the art according to the kind of above-described foodstuff.
次に、前記した本実施形態に係るユズ種子抽出物含有組成物を有効成分として含有する医薬品について説明する。
≪医薬品≫
本実施形態に係る医薬品とは、前記した組成物を有効成分として含有する医薬品であり、骨格筋増量用や体脂肪低減用の医薬品として利用することができる。
そして、本実施形態に係る医薬品とは、薬剤としての操作性、あるいは生体に投与された際の吸収性等を向上させるため、前記した組成物を、常法に従い適当な賦形剤等の医薬品用担体と組合せて製剤化することが好ましい。
また、本実施形態に係る医薬品は、種々の剤型での投与が可能であり、例えば、経口投与剤としては、カプセル剤、錠剤、顆粒剤、細粒剤、シロップ剤、ドライシロップ剤が挙げられる。また、非経口投与剤としては、軟膏、経皮吸収性テープ等の経皮吸収剤、注射剤、坐薬、膣坐薬、噴霧剤等の経鼻投与剤が挙げられる。
Next, the pharmaceutical which contains the above-mentioned yuzu seed extract containing composition which concerns on this embodiment as an active ingredient is demonstrated.
≪Pharmaceuticals≫
The drug according to the present embodiment is a drug containing the above-described composition as an active ingredient, and can be used as a drug for increasing skeletal muscle or reducing body fat.
The pharmaceutical product according to this embodiment is a pharmaceutical product such as an appropriate excipient according to a conventional method in order to improve operability as a drug or absorbability when administered to a living body. It is preferable to formulate in combination with a carrier for use.
In addition, the pharmaceutical agent according to the present embodiment can be administered in various dosage forms, and examples of the oral administration agent include capsules, tablets, granules, fine granules, syrups, and dry syrups. . Examples of parenteral administration agents include transdermal absorption agents such as ointments and transdermal absorption tapes, and nasal administration agents such as injections, suppositories, vaginal suppositories, and sprays.
次に、前記した本実施形態に係るユズ種子抽出物含有組成物、食品および医薬品の製造方法について説明する。
≪ユズ種子抽出物含有組成物等の製造方法≫
本実施形態に係るユズ種子抽出物含有組成物の製造方法を下記の通り説明する。
Next, a method for producing a yuzu seed extract-containing composition, food, and pharmaceutical according to the above-described embodiment will be described.
≪Method for producing composition containing yuzu seed extract≫
The manufacturing method of the yuzu seed extract containing composition which concerns on this embodiment is demonstrated as follows.
前記した本実施形態に係るユズ種子抽出物含有組成物は、ユズ種子及びその乾燥物を破砕したもの（以下、単に「ユズ種子原料」と略記する場合がある）を、極性溶媒で抽出した処理物である。 The above-described composition for containing a yuzu seed extract according to the present embodiment is a treatment in which a yuzu seed and a dried product thereof are crushed (hereinafter sometimes simply referred to as “yuzu seed raw material”) are extracted with a polar solvent. It is a thing.
ユズ種子原料の極性溶媒を用いた抽出の温度は、０℃〜極性溶媒の沸点程度であり、通常は常温で行う。例えば、極性溶媒としてエタノールを使用する場合、抽出効率の観点から、０℃以上７０℃未満が好ましく、５℃以上６０℃以下がより好ましい。例えば、極性溶媒として水を使用する場合、抽出効率の観点から、０℃以上１００℃以下が好ましく、２５℃以上１００℃以下がより好ましい。 The extraction temperature of the yuzu seed raw material using a polar solvent ranges from 0 ° C. to the boiling point of the polar solvent, and is usually performed at room temperature. For example, when ethanol is used as the polar solvent, it is preferably 0 ° C. or higher and lower than 70 ° C., more preferably 5 ° C. or higher and 60 ° C. or lower from the viewpoint of extraction efficiency. For example, when water is used as the polar solvent, it is preferably 0 ° C. or higher and 100 ° C. or lower, more preferably 25 ° C. or higher and 100 ° C. or lower, from the viewpoint of extraction efficiency.
抽出時間は、１分〜２４時間が好ましいが、これより長時間抽出を行ってもよい。抽出は、静置、攪拌のいずれの手法を用いてもよい。ユズ種子原料に１〜５０倍量、好ましくは５〜２０倍量程度の極性溶媒を加え抽出後、定法に従い希釈、濃縮、乾燥、精製等を行うことでユズ種子抽出物含有組成物を得ることができる。 The extraction time is preferably 1 minute to 24 hours, but the extraction may be performed for a longer time. Extraction may be performed by either standing or stirring. A uzu seed extract-containing composition is obtained by adding 1 to 50 times, preferably 5 to 20 times, a polar solvent to a yuzu seed raw material, followed by extraction, dilution, concentration, drying, purification, etc. according to a conventional method. Can do.
極性溶媒としては、食品添加物の抽出溶剤となり得る極性溶媒であれば特に限定されず、例えば、アセトン、エタノール、エチルメチルケトン、グリセリン、酢酸エチル、酢酸メチル、ジエチルエーテル、シクロヘキサン、ジクロロメタン、食用油脂、１，１，１，２−テトラフルオロエタン、１，１，２−トリクロロエテン、１−ブタノール、２−ブタノール、１−プロパノール、２−プロパノール、プロピレングリコール、ヘキサン、水、メタノール等から選択される１又は複数の有機溶媒を用いることができる。
これらのうち好ましくは、エタノール（１０体積％以上１００体積％以下）、メタノール（１０体積％以上９９．５体積％未満）、１−ブタノール（３０体積％以上９９．５体積％未満）、ヘキサン（５体積％７０体積％未満）及び水から選択される有機溶媒を用いることができ、より好ましくは、エタノール又は水を用いることができ、最も好ましくはエタノールを用いることができる。
例えば、極性溶媒として、１０体積％以上１００体積％以下のエタノール溶媒を用いることができ、好ましくは５０体積％以上１００体積％以下のエタノール溶媒を用いることができ、より好ましくは７０体積％程度のエタノール溶媒用いることができる。なお、７０体積％のエタノール溶媒とは、水とエタノールの体積比３：７の混合物を指す。
The polar solvent is not particularly limited as long as it is a polar solvent that can be an extraction solvent for food additives. For example, acetone, ethanol, ethyl methyl ketone, glycerin, ethyl acetate, methyl acetate, diethyl ether, cyclohexane, dichloromethane, edible fats and oils 1,1,1,2-tetrafluoroethane, 1,1,2-trichloroethene, 1-butanol, 2-butanol, 1-propanol, 2-propanol, propylene glycol, hexane, water, methanol, etc. One or more organic solvents can be used.
Of these, ethanol (10% by volume to 100% by volume), methanol (10% by volume to less than 99.5% by volume), 1-butanol (30% by volume to less than 99.5% by volume), hexane ( 5% by volume and less than 70% by volume) and an organic solvent selected from water can be used, more preferably ethanol or water can be used, and most preferably ethanol can be used.
For example, as a polar solvent, an ethanol solvent of 10% by volume to 100% by volume can be used, preferably an ethanol solvent of 50% by volume to 100% by volume can be used, and more preferably about 70% by volume. An ethanol solvent can be used. The 70% by volume ethanol solvent refers to a mixture of water and ethanol in a volume ratio of 3: 7.
一態様において、本発明のユズ種子抽出物含有組成物は、上記のとおり、ユズ種子の有機溶媒抽出物であることが好ましく、ユズ種子のアルコール抽出物であることがより好ましく、ユズ種子のエタノール抽出物であることが特に好ましい。 In one embodiment, the composition of the yuzu seed extract of the present invention is preferably an organic solvent extract of yuzu seed, more preferably an alcohol extract of yuzu seed, as described above, and ethanol of yuzu seed. An extract is particularly preferred.
なお、本実施形態に係る食品および医薬品の製造方法については、前記の方法によって製造したユズ種子抽出物含有組成物を、食品や医薬品の材料に混合させ、その後は、当業者に公知の食品や医薬品の製造方法によって製造すればよい。 In addition, about the manufacturing method of the foodstuff and pharmaceutical which concern on this embodiment, the uzu seed extract containing composition manufactured by the said method is mixed with the material of a foodstuff or a pharmaceutical, and after that food well-known to those skilled in the art and What is necessary is just to manufacture with the manufacturing method of a pharmaceutical.
次に、本発明の要件を満たす実施例とそうでない比較例とを例示して、本発明に係るユズ種子抽出物含有組成物、食品および医薬品について説明する。 Next, examples that satisfy the requirements of the present invention and comparative examples that are not so illustrated will be described, and the composition containing uzu seed extract, food, and pharmaceuticals according to the present invention will be described.
［実験１：ＫＫＡｙマウスを用いた動物実験（骨格筋増量および体脂肪低減）］
（実験飼育の条件）
糖尿病発症モデルマウスとして３週齢のＫＫＡｙマウスを日本クレアより購入し、７日間の予備飼育後に実験飼育を行った。なお、マウスの飼育条件は、温度２３±１℃、湿度５５±１０％、午前７時〜午後７時の間点灯（その他は消灯）、水と飼料は自由摂取させた。
[Experiment 1: Animal experiment using KKAy mice (skeletal muscle gain and body fat reduction)]
(Conditions for experimental breeding)
A 3-week-old KKAy mouse was purchased from CLEA Japan as a diabetes onset model mouse, and experimental breeding was performed after 7 days of preliminary breeding. The mice were raised under the conditions of a temperature of 23 ± 1 ° C., a humidity of 55 ± 10%, lighted from 7:00 am to 7:00 pm (others were turned off), and water and feed were ingested freely.
（実験飼料の組成）
実験飼料は、ＡＩＮ−９３Ｇを用い、これにユズ種子抽出物を３質量％となるように含有させた飼料、リモノイドアグリコン、リモノイドグリコシド（ともにユズ種子抽出物群の摂取量と等量になるように調整）を含有させた飼料を使用した。
なお、リモノイドアグリコンおよびリモノイドグリコシドは、ユズ種子抽出物から分画して得られたものを使用した。
(Composition of experimental feed)
The experimental feed used was AIN-93G, which contained 3% by weight of yuzu seed extract, limonoid aglycone, limonoid glycoside (both were equivalent to the intake of the yuzu seed extract group) The feed containing the adjustment was used.
In addition, limonoid aglycone and limonoid glycoside used what was obtained by fractionating from a yuzu seed extract.
（実験結果の測定方法）
コントロール群、リモノイドグリコシド添加群、リモノイドアグリコン添加群、ユズ種子抽出物添加群は、各群８匹または９匹で７日間の予備飼育後、２８日間実験飼料で飼育した。
(Measurement method of experimental results)
In the control group, the limonoid glycoside addition group, the limonoid aglycone addition group, and the yuzu seed extract addition group, each group was bred on experimental feed for 28 days after preliminary bred for 7 or 8 animals.
骨格筋の筋肉量の変動を確認するため、実験飼育開始後２８日目のマウスについて、マウス体重に対する「腓腹筋」の重量割合（＝各筋肉重量（ｇ）／マウス体重（ｇ））を計測した。
また、脂肪の量の変動を測定するため、実験飼育開始後２８日目のマウスについて、マウス体重に対する「腎臓周囲脂肪」、「腸間膜脂肪」、「精巣上体周囲脂肪」、「皮下脂肪」の重量割合（＝各脂肪重量（ｇ）／マウス体重（ｇ））を計測した。
そして、計測した筋肉および脂肪の重量割合について、各群の平均値を算出した。
なお、前記筋肉および脂肪の重量の測定は、各組織を摘出し、生理食塩水で洗浄後、脱脂綿で水分を除去して行った。
In order to confirm the variation of the muscle mass of skeletal muscle, the weight ratio of the “gastrocnemius muscle” to the mouse body weight (= each muscle weight (g) / mouse body weight (g)) was measured for the mice on the 28th day after the start of the experimental breeding. .
In addition, in order to measure changes in the amount of fat, for mice on the 28th day after the start of experimental breeding, “perirenal fat”, “mesenteric fat”, “epididymal fat”, “subcutaneous fat” relative to the mouse weight The weight ratio (= each fat weight (g) / mouse body weight (g)) was measured.
And the average value of each group was computed about the weight ratio of the measured muscle and fat.
The weight of the muscle and fat was measured by removing each tissue, washing with physiological saline, and removing moisture with absorbent cotton.
図１は、実験飼育開始後２８日目のＫＫＡｙマウスの腓腹筋の重量割合を示す。また、図２、３、４、５は、それぞれ、実験飼育開始後２８日目のＫＫＡｙマウスの腎臓周囲脂肪、腸間膜脂肪、精巣上体周囲脂肪、皮下脂肪の重量割合を示す。
なお、図中の「ｐ＜数値ｖｓ ｃｏｎｔｒｏｌ」とは、ｃｏｎｔｒｏｌ群に対してｐ値が表記した数値より小さいという意味である。また、図中の「ｔｏｔａｌ」とは、ユズ種子抽出物添加群を示している。
FIG. 1 shows the weight ratio of the gastrocnemius muscle of KKAy mice on the 28th day after the start of experimental breeding. 2, 3, 4, and 5 show the weight ratios of the perirenal fat, mesenteric fat, epididymal fat and subcutaneous fat of KKAy mice on the 28th day after the start of the experimental breeding, respectively.
In the figure, “p <numerical value vs control” means that the p value for the control group is smaller than the numerical value described. Further, “total” in the figure indicates a yuzu seed extract added group.
（実験結果の検討）
図１の結果が示すように、リモノイドアグリコン添加群は腓腹筋の重量割合を上昇させるという結果となった。
(Examination of experimental results)
As the result of FIG. 1 shows, the limonoid aglycone addition group increased the weight ratio of the gastrocnemius muscle.
図２、３、４、５の結果が示すように、リモノイドアグリコン添加群は、腎臓周囲脂肪、腸間膜脂肪、精巣上体周囲脂肪、皮下脂肪の重量割合のいずれの重量割合も低下するという結果となった。 As shown in the results of FIGS. 2, 3, 4, and 5, in the limonoid aglycone addition group, all of the weight ratios of perirenal fat, mesenteric fat, epididymal fat, and subcutaneous fat are reduced. As a result.
以上より、本発明に係るユズ種子抽出物含有組成物は、骨格筋を増量させるという効果、および、体脂肪を低減させるという効果があることを確認できた。
また、実験飼料としてリモノイドアグリコンを所定量含有（２.５質量％、４質量％）させたもので、実験１と同様の実験を行ったが、いずれの実験結果も、骨格筋（腓腹筋）を増加させるとともに、体脂肪（腎臓周囲脂肪、腸間膜脂肪、精巣上体周囲脂肪、皮下脂肪）を低減させるという結果となった。よって、リモノイドアグリコンを２．５〜４質量％含有するユズ種子抽出物であれば、骨格筋を増量させる効果および体脂肪を低減させる効果を確実に発揮できることも確認できた。
From the above, it was confirmed that the yuzu seed extract-containing composition according to the present invention has the effect of increasing the amount of skeletal muscle and the effect of reducing body fat.
In addition, a predetermined amount (2.5% by mass, 4% by mass) of limonoid aglycone was used as an experimental feed, and the same experiment as in Experiment 1 was performed. As a result, the body fat (perirenal fat, mesenteric fat, epididymal fat, subcutaneous fat) was reduced. Therefore, it was also confirmed that a yuzu seed extract containing 2.5-4% by mass of limonoid aglycone can reliably exhibit the effect of increasing skeletal muscle and the effect of reducing body fat.
［実験２：ユズ種子抽出物に含まれるリモノイドアグリコン］
実験１で得られたリモノイドアグリコンをシリカゲルカラム（ｄａｉｓｏｇｅｌ １００２Ａ ＩＲ６０−４０／６３Ａ）を用いて分画し、４種のリモノイドアグリコンを得た。これらのサンプルを定法に基づきＬＣ−ＭＳ解析に供した結果を図６〜９に示す。
[Experiment 2: Limonoid aglycone contained in Yuzu seed extract]
The limonoid aglycone obtained in Experiment 1 was fractionated using a silica gel column (daiisogel 1002A IR60-40 / 63A) to obtain four types of limonoid aglycones. The results of subjecting these samples to LC-MS analysis based on a conventional method are shown in FIGS.
（実験結果の検討）
図６から、このサンプルのｍ／ｚは４７３．２１６２であり、このリモノイドアグリコンがデアセチルノミリン（［Ｍ＋Ｈ］＋は４７３．２１７５）であることがわかる。また、図７から、このサンプルのｍ／ｚは４７１．２００６であり、このリモノイドアグリコンがリモニン（［Ｍ＋Ｈ］＋は４７１．２０１９）であることがわかる。また、図８より、このサンプルのｍ／ｚは５１５．２２８３であり、このリモノイドアグリコンがノミリン（［Ｍ＋Ｈ］＋は５１５．２２８１）であることがわかる。また、図９より、このサンプルのｍ／ｚは４５５．２０５５であり、このリモノイドアグリコンがオバクノン（［Ｍ＋Ｈ］＋は４５５．２０７０）であることがわかる。
(Examination of experimental results)
FIG. 6 shows that m / z of this sample is 473.2162, and this limonoid aglycone is deacetylnomyrin ([M + H] + is 473.2175). Further, FIG. 7 shows that m / z of this sample is 471.2006, and this limonoid aglycone is limonin ([M + H] + is 471.2019). Further, FIG. 8 shows that m / z of this sample is 515.2283, and that this limonoid aglycone is nomiline ([M + H] + is 515.2281). Further, FIG. 9 shows that the m / z of this sample is 455.2055, and that this limonoid aglycone is obacunone ([M + H] + is 455.2070).
本発明に係るユズ種子抽出物含有組成物、食品および医薬品について、実施の形態及び実施例を示して詳細に説明したが、本発明の趣旨は前記した内容に限定されることなく、特許請求の範囲の記載に基づいて改変・変更等することができることはいうまでもない。 The yuzu seed extract-containing composition, food and medicine according to the present invention have been described in detail with reference to the embodiments and examples, but the gist of the present invention is not limited to the above-described content, Needless to say, modifications and changes can be made based on the description of the range.
Claims (6)
骨格筋増量用であることを特徴とするユズ種子抽出物含有組成物。 Contains limonoid aglycone from Yuzu seed extract,
A composition containing a yuzu seed extract, which is used for increasing skeletal muscle.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013226583A JP2015086181A (en) | 2013-10-31 | 2013-10-31 | Citrus junos seed extract-containing composition, food product and pharmaceutical |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013226583A JP2015086181A (en) | 2013-10-31 | 2013-10-31 | Citrus junos seed extract-containing composition, food product and pharmaceutical |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2015086181A true JP2015086181A (en) | 2015-05-07 |
Family
ID=53049358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013226583A Pending JP2015086181A (en) | 2013-10-31 | 2013-10-31 | Citrus junos seed extract-containing composition, food product and pharmaceutical |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2015086181A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105560208A (en) * | 2016-01-21 | 2016-05-11 | 中国中药公司 | Wild buckwheat rhizome preparation and preparation method thereof |
| CN106383195A (en) * | 2016-08-29 | 2017-02-08 | 贵州信邦制药股份有限公司 | Identification method of cortex dictamni in anti-rheumatism medicinal liquor |
| WO2018236007A1 (en) * | 2017-06-21 | 2018-12-27 | 주식회사 마린테크노 | A whitening cosmetic composition comprising an extract of Yuzu citrus as an active ingredient |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06199618A (en) * | 1987-09-25 | 1994-07-19 | Taiyo Kagaku Co Ltd | Pest control agent |
| JP2007297343A (en) * | 2006-05-01 | 2007-11-15 | Oriza Yuka Kk | Lipid metabolism improver |
| JP2008156294A (en) * | 2006-12-25 | 2008-07-10 | Lion Corp | Myoblast activator |
| JP2009013194A (en) * | 2007-06-29 | 2009-01-22 | Shizen Chiyuryoku Kenkyusho:Kk | Essential oil and solid matter derived from seed of yuzu orange |
| KR20120003993A (en) * | 2010-07-06 | 2012-01-12 | 주식회사 마크로케어 | Citron seed-derived flavonoid clathrate, preparation method thereof and use thereof |
| JP2012180309A (en) * | 2011-03-02 | 2012-09-20 | Satoshi Mochizuki | Hepatopathy prophylactic agent |
-
2013
- 2013-10-31 JP JP2013226583A patent/JP2015086181A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06199618A (en) * | 1987-09-25 | 1994-07-19 | Taiyo Kagaku Co Ltd | Pest control agent |
| JP2007297343A (en) * | 2006-05-01 | 2007-11-15 | Oriza Yuka Kk | Lipid metabolism improver |
| JP2008156294A (en) * | 2006-12-25 | 2008-07-10 | Lion Corp | Myoblast activator |
| JP2009013194A (en) * | 2007-06-29 | 2009-01-22 | Shizen Chiyuryoku Kenkyusho:Kk | Essential oil and solid matter derived from seed of yuzu orange |
| KR20120003993A (en) * | 2010-07-06 | 2012-01-12 | 주식회사 마크로케어 | Citron seed-derived flavonoid clathrate, preparation method thereof and use thereof |
| JP2012180309A (en) * | 2011-03-02 | 2012-09-20 | Satoshi Mochizuki | Hepatopathy prophylactic agent |
Non-Patent Citations (1)
| Title |
|---|
| 三宅 正起: "カンキツリモノイドの生化学と生理活性", 食品工業 第３６巻第２４号, vol. 第36巻第24号, JPN6017007127, 1993, pages 26 - 34, ISSN: 0003509772 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105560208A (en) * | 2016-01-21 | 2016-05-11 | 中国中药公司 | Wild buckwheat rhizome preparation and preparation method thereof |
| CN106383195A (en) * | 2016-08-29 | 2017-02-08 | 贵州信邦制药股份有限公司 | Identification method of cortex dictamni in anti-rheumatism medicinal liquor |
| CN106383195B (en) * | 2016-08-29 | 2018-08-21 | 贵州信邦制药股份有限公司 | The discrimination method of the root bark of shaggy-fruited dittany in anti-rheumatism medicinal liquor |
| WO2018236007A1 (en) * | 2017-06-21 | 2018-12-27 | 주식회사 마린테크노 | A whitening cosmetic composition comprising an extract of Yuzu citrus as an active ingredient |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6541582B2 (en) | Yuzu seed extract-containing composition, food for increasing skeletal muscle mass, and method for producing yuzu seed extract-containing composition | |
| Abbas et al. | Potential role and mechanism of mulberry extract in immune modulation: focus on chemical compositions, mechanistic insights, and extraction techniques | |
| JP2006512330A (en) | Preparation and use of triterpenoid sapogenin compounds extracted from bamboo | |
| JP6802256B2 (en) | GLP-1 secretion promoting composition and method for producing the same | |
| JP2016199536A (en) | Compositions for enhancing muscles and improving metabolic syndrome, as well as improving qol | |
| WO2004030683A1 (en) | Remedies | |
| JP2011207776A (en) | Adiponectin production-promoting agent | |
| JP2015086181A (en) | Citrus junos seed extract-containing composition, food product and pharmaceutical | |
| JP2011057597A (en) | Hyperglycemic inhibitor | |
| JP2011057598A (en) | Lipid metabolism-improving agent | |
| JP4922551B2 (en) | Maple syrup fortified with bioactive phenolic compounds | |
| JP2011057599A (en) | Energy metabolism-promoting agent | |
| JP2011057585A (en) | Antidepressant agent | |
| JP2017079712A (en) | Krill oil composition | |
| JP6063543B2 (en) | Preventive or ameliorating agent for overactive bladder | |
| JP2015086137A (en) | Yuzu seed extract-containing composition, food and medicine | |
| KR102573074B1 (en) | Sirtuin-1 activation agent and skin cosmetic for activating sirtuin 1 | |
| JP6245867B2 (en) | PPARγ activity improving agent and oral composition using the same | |
| JP5897354B2 (en) | Preventive or ameliorating agent for overactive bladder | |
| JP5770504B2 (en) | Adiponectin production promoter | |
| JP2002322191A (en) | Sesaminol glycoside, method of producing the same and antioxidant | |
| JP6782956B2 (en) | Absorption enhancer | |
| JP2008081440A (en) | Aromatase activity promoter | |
| JP2019026639A (en) | Method for producing an extract having peroxisome proliferator-activated receptor activation action from Eucalyptus | |
| JP2024113518A (en) | Insulin secretion enhancer and its use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160614 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20160720 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170307 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170417 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170627 |